Effect of the Quadratus Lumborum Block Versus the Lumbar Plexus for Spiral Thighplasty Surgery (QLB&LPB)

March 15, 2026 updated by: Amal Gouda Elsayed Safan, Menoufia University

Comparing the Early Postoperative Analgesic Effect of the Transmuscular Quadratus Lumborum Block Versus the Lumbar Plexus Block for Patients Undergoing Spiral Thighplasty Surgery

Whether trans muscular QLB provides postoperative analgesia compared with LPB after thigh lift surgery

Study Overview

Detailed Description

Adequate analgesia after spiral thigh reduction (thigh lift) is essential for early mobilization and patient satisfaction. Quadratus lumborum block (QLB) has shown analgesic efficacy comparable to lumbar plexus block (LPB) for hip area surgery with potential advantages in motor-sparing and safety

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shibin El Kom
      • Cairo, Shibin El Kom, Egypt, 32511
        • Faculty of medicine,Menofia university hospitals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ASA ( American Society of Anaesthesia) I-II
  • elective bilateral spiral thigh lift under general anesthesia
  • consent to regional block and trial participation

Exclusion Criteria:

  • Coagulopathy or therapeutic anticoagulation not meeting ASRA safety windows
  • infection at injection sites
  • allergy to local anesthetics
  • preexisting significant neuropathy
  • BMI > 35 kg/m² if impeding ultrasound visualization; renal/hepatic failure; pregnancy; inability to use NRS; chronic opioid use >60 mg oral morphine equivalents/day; contraindication to study analgesics.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Group QLB
Ultrasound-Guided Trans-muscular QLB
With the patient lateral decubitus position, a low-frequency curvilinear probe in the 'Shamrock' view at L2-L4. In-plane posterior-to-anterior needle advancement through the Quadratus lumborum to the interfascial plane anterior to QL and posterior to Psoas major. Inject 30 mL Bupivacaine 0.25% after negative aspiration and hydrodissection to confirm proper spread . Then the patient will be turned to the other side, and the block will be done with the same technique
Other: Group LPB
Ultrasound-Guided Posterior Lumbar Plexus (Psoas Compartment) Block
Lateral decubitus, Shamrock view to identify the Psoas compartment; in-plane needle advancement to the Psoas compartment adjacent to the transverse process. Inject 30 mL of Bupivacaine 0.25% in 5 mL increments, aspirating frequently. This will be done in the same position for both sides

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual analogue scale score
Time Frame: 24 hours
Visual analogue scale score at 1st,6th,12th and 24 h (where 0 is interpreted as no pain, 1-4 mild pain, 5-6 moderate pain, 7-10 severe pain)
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time for first analgesic request
Time Frame: 24 hours
first analgesic request
24 hours
Opioid consumption
Time Frame: 24 hours
cumulative opioid consumption
24 hours
Time to walk >30 (meter)
Time Frame: 24 hours
walk >30 (meter)
24 hours
Performance Time
Time Frame: minutes
block performance time
minutes
The number of patients who develop block-related complications
Time Frame: 24 hours
nausea and vomiting , hypotension
24 hours
the patients Satisfaction questionnaire
Time Frame: 24 hours
pateints are either : Dissatisfied Neither satisfied nor dissatisfied Satisfied Very satisfied
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: AMAL G SAFAN, MD, Menoufia University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 13, 2025

Primary Completion (Actual)

February 28, 2026

Study Completion (Actual)

March 14, 2026

Study Registration Dates

First Submitted

November 28, 2025

First Submitted That Met QC Criteria

December 11, 2025

First Posted (Actual)

December 12, 2025

Study Record Updates

Last Update Posted (Actual)

March 17, 2026

Last Update Submitted That Met QC Criteria

March 15, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Analgesia

Clinical Trials on Ultrasound-Guided Trans-muscular QLB

Subscribe